QIAGEN to Acquire Parse Biosciences
November 4, 2025
QIAGEN entered into a definitive agreement to fully acquire Parse Biosciences, expanding its Sample technologies portfolio into the single-cell sequencing market. The deal is expected to close in late 2025/December 2025 for an upfront payment of approximately $225 million in cash, plus up to $55 million in milestone payments.
- Buyers
- QIAGEN N.V.
- Targets
- Parse Biosciences
- Industry
- Biotechnology
- Location
- Washington, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.